首页> 外文期刊>Frontiers in Pharmacology >Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response
【24h】

Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response

机译:中国古代中医草本配方黄利杰腐汤作为新辅助治疗化疗,通过改善腹泻和肿瘤反应

获取原文
       

摘要

Background Diarrhea is a major gastrointestinal complication in cancer patients receiving chemotherapy. Prognosis and treatment of chemotherapy-induced diarrhea (CID) remain unsatisfactory. This study aims to explore the potential of an ancient Chinese Medicine herbal formula Huanglian Jiedu Decoction (HLJDD) as an adjuvant treatment on CID. Method HLJDD extract was prepared by GMP manufacturing standard with quality and stability being checked. 5-fluorouracil (5-Fu) and irinotecan (CPT-11)-induced diarrhea model in mice was established and pre-, co- and post-treatment of HLJDD was implemented. Mechanism of action was explored by detecting related protein expression. In addition, the effect of HLJDD on diarrhea and tumor response induced by clinical regimens FOLFOX and FOLFIRI was measured in murine orthotopic colorectal cancer model. Results HLJDD exhibited consistency in quality and stability after 24-month storage. Pre-treatment of HLJDD, but not co-treatment or post-treatment, could significantly improve the diarrhea score, body weight loss and intestinal damage in 5-Fu- and CPT-11-treated mice. Pre-treatment of HLJDD reduced cell apoptosis in the intestine of chemotherapy-treated mice, and promoted renewal of intestinal cell wall. CD44 was predicted as the potential target of HLJDD-containing compounds in CID. HLJDD pre-treatment induced presentation of CD44-postive cells in the intestine of chemotherapy-treated mice, and initiated expression of stemness-associated genes. Transcriptional products of the downstream Wnt signaling of CD44 were elevated. Furthermore, pre-treatment of HLJDD could significantly improve the tumor response of clinical chemotherapy regimens FOLFOX and FOLFIRI in orthotopic colorectal cancer, and reduce diarrhea and intestinal damage. Conclusion: Our study suggests the potential of HLJDD as a neoadjuvant treatment of chemotherapy by reducing diarrhea and improving tumor response.
机译:背景技术腹泻是癌症患者接受化疗的主要胃肠共产功能。预后和化疗诱导的腹泻(CID)的治疗仍然不令人满意。本研究旨在探讨古代中医草本公式黄连jiedu汤(HLJDD)作为CID辅助治疗的潜力。方法HLJDD提取物由GMP制造标准制备,并检查质量和稳定性。建立了5-氟尿嘧啶(5-FU)和Irinotecan(CPT-11)诱导小鼠的腹泻模型,并进行了HLJDD的共同,共同治疗。通过检测相关蛋白质表达探索了作用机制。此外,在小鼠原位结直肠癌模型中测量了HLJDD对临床治疗方案和Folfiri诱导的腹泻和肿瘤反应的影响。结果HLJDD在24个月储存后的质量和稳定性的一致性。 HLJDD的预处理,但不合作或后治疗,可以显着改善5-FU和CPT-11处理的小鼠中的腹泻评分,体重减轻和肠损伤。化疗处理的小鼠肠道HLJDD降低细胞凋亡,促进了肠道细胞壁的更新。预测CD44作为CID中含HLJDD化合物的潜在靶标。 HLJDD预处理诱导化疗处理的小鼠肠道CD44末期细胞的呈递,并引发了茎相关基因的表达。 CD44的下游Wnt信号传导的转录产物升高。此外,HLJDD的预处理可以显着改善临床化疗方案叶子和Folfiri在原位结肠直肠癌中的肿瘤反应,并降低腹泻和肠道损伤。结论:我们的研究表明,通过减少腹泻和改善肿瘤反应,HLJDD作为内辅助治疗化疗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号